CY1123222T1 - Χρηση των υποδοχεων ccr3 - Google Patents
Χρηση των υποδοχεων ccr3Info
- Publication number
- CY1123222T1 CY1123222T1 CY20201100678T CY201100678T CY1123222T1 CY 1123222 T1 CY1123222 T1 CY 1123222T1 CY 20201100678 T CY20201100678 T CY 20201100678T CY 201100678 T CY201100678 T CY 201100678T CY 1123222 T1 CY1123222 T1 CY 1123222T1
- Authority
- CY
- Cyprus
- Prior art keywords
- eosinophilic
- alkyl
- macular degeneration
- solar
- syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Structure Of Transmissions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162937 | 2012-04-03 | ||
| EP13713199.1A EP2833884B1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
| PCT/EP2013/056864 WO2013149986A1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123222T1 true CY1123222T1 (el) | 2021-10-29 |
Family
ID=48040249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100678T CY1123222T1 (el) | 2012-04-03 | 2020-07-23 | Χρηση των υποδοχεων ccr3 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20130261153A1 (https=) |
| EP (3) | EP4389217A3 (https=) |
| JP (2) | JP2015512432A (https=) |
| KR (5) | KR20140144200A (https=) |
| CN (2) | CN104220073A (https=) |
| AU (1) | AU2013245027B2 (https=) |
| BR (1) | BR112014023795B1 (https=) |
| CA (1) | CA2869269C (https=) |
| CL (1) | CL2014002523A1 (https=) |
| CY (1) | CY1123222T1 (https=) |
| DK (1) | DK2833884T3 (https=) |
| EA (1) | EA032263B1 (https=) |
| ES (2) | ES2811554T3 (https=) |
| HR (1) | HRP20201165T1 (https=) |
| HU (1) | HUE051648T2 (https=) |
| IL (1) | IL234262A (https=) |
| IN (1) | IN2014DN06989A (https=) |
| LT (1) | LT2833884T (https=) |
| MX (1) | MX2014011786A (https=) |
| NZ (1) | NZ628882A (https=) |
| PH (1) | PH12014502239A1 (https=) |
| PL (1) | PL2833884T3 (https=) |
| PT (1) | PT2833884T (https=) |
| RS (1) | RS60665B1 (https=) |
| SI (1) | SI2833884T1 (https=) |
| SM (1) | SMT202000499T1 (https=) |
| WO (1) | WO2013149986A1 (https=) |
| ZA (1) | ZA201406082B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| JP6684363B2 (ja) | 2016-11-24 | 2020-04-22 | キリシマ精工株式会社 | 歯列矯正具 |
| MY199462A (en) * | 2017-04-05 | 2023-10-30 | Alkahest Inc | Methods and compositions for treating retina-associated disease using ccr3-inhibitors |
| SG11201909245PA (en) | 2017-04-05 | 2019-11-28 | Alkahest Inc | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
| CA3076017A1 (en) * | 2017-10-13 | 2019-04-18 | Alkahest, Inc. | Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors |
| MY198220A (en) | 2018-05-15 | 2023-08-14 | Alkahest Inc | Treatment Of Aging-Associated Disease With Modulators Of Leukotriene A4 Hydrolase |
| CN112789044A (zh) * | 2018-09-26 | 2021-05-11 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
| AU2021287906B2 (en) | 2020-06-11 | 2025-09-11 | Alkahest Inc. | Methods of improving retina-associated disease outcome using CCR3-inhibitors |
| AU2022376563A1 (en) | 2021-11-01 | 2023-12-07 | Alkahest, Inc. | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| BRPI0108923B8 (pt) * | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| US8030003B2 (en) * | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| US8008092B2 (en) * | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| WO2010069979A1 (en) * | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| WO2010138591A1 (en) * | 2009-05-26 | 2010-12-02 | University Of Kentucky Research Foundation | Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2020115836A1 (ja) * | 2018-12-05 | 2020-06-11 | 東浜工業株式会社 | ブロワー装置 |
-
2013
- 2013-03-27 US US13/851,564 patent/US20130261153A1/en not_active Abandoned
- 2013-04-02 CA CA2869269A patent/CA2869269C/en active Active
- 2013-04-02 CN CN201380016333.7A patent/CN104220073A/zh active Pending
- 2013-04-02 SM SM20200499T patent/SMT202000499T1/it unknown
- 2013-04-02 CN CN201910406245.7A patent/CN110384699A/zh active Pending
- 2013-04-02 NZ NZ628882A patent/NZ628882A/en unknown
- 2013-04-02 DK DK13713199.1T patent/DK2833884T3/da active
- 2013-04-02 EP EP24158785.6A patent/EP4389217A3/en active Pending
- 2013-04-02 WO PCT/EP2013/056864 patent/WO2013149986A1/en not_active Ceased
- 2013-04-02 EP EP20174399.4A patent/EP3763369B1/en active Active
- 2013-04-02 HR HRP20201165TT patent/HRP20201165T1/hr unknown
- 2013-04-02 PL PL13713199T patent/PL2833884T3/pl unknown
- 2013-04-02 HU HUE13713199A patent/HUE051648T2/hu unknown
- 2013-04-02 AU AU2013245027A patent/AU2013245027B2/en active Active
- 2013-04-02 KR KR1020147027679A patent/KR20140144200A/ko not_active Ceased
- 2013-04-02 BR BR112014023795-6A patent/BR112014023795B1/pt active IP Right Grant
- 2013-04-02 KR KR1020207011392A patent/KR20200044988A/ko not_active Ceased
- 2013-04-02 LT LTEP13713199.1T patent/LT2833884T/lt unknown
- 2013-04-02 JP JP2015503847A patent/JP2015512432A/ja active Pending
- 2013-04-02 SI SI201331753T patent/SI2833884T1/sl unknown
- 2013-04-02 KR KR1020257028220A patent/KR20250133980A/ko active Pending
- 2013-04-02 ES ES13713199T patent/ES2811554T3/es active Active
- 2013-04-02 KR KR1020227031439A patent/KR20220132012A/ko not_active Ceased
- 2013-04-02 IN IN6989DEN2014 patent/IN2014DN06989A/en unknown
- 2013-04-02 RS RS20200868A patent/RS60665B1/sr unknown
- 2013-04-02 EP EP13713199.1A patent/EP2833884B1/en active Active
- 2013-04-02 EA EA201401083A patent/EA032263B1/ru unknown
- 2013-04-02 KR KR1020217015686A patent/KR20210063481A/ko not_active Ceased
- 2013-04-02 MX MX2014011786A patent/MX2014011786A/es unknown
- 2013-04-02 ES ES20174399T patent/ES2987267T3/es active Active
- 2013-04-02 PT PT137131991T patent/PT2833884T/pt unknown
-
2014
- 2014-08-19 ZA ZA2014/06082A patent/ZA201406082B/en unknown
- 2014-08-24 IL IL234262A patent/IL234262A/en active IP Right Grant
- 2014-09-24 CL CL2014002523A patent/CL2014002523A1/es unknown
- 2014-10-03 PH PH12014502239A patent/PH12014502239A1/en unknown
- 2014-12-15 US US14/570,298 patent/US20150099783A1/en not_active Abandoned
-
2015
- 2015-11-30 US US14/953,480 patent/US20160081998A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/658,918 patent/US20170319567A1/en not_active Abandoned
- 2017-12-22 JP JP2017246173A patent/JP2018080183A/ja not_active Withdrawn
-
2020
- 2020-07-23 CY CY20201100678T patent/CY1123222T1/el unknown
- 2020-08-19 US US16/997,772 patent/US20200375971A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123222T1 (el) | Χρηση των υποδοχεων ccr3 | |
| CY1124446T1 (el) | Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης | |
| CY1122712T1 (el) | ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ | |
| CY1123988T1 (el) | Ενωση πυριδινης | |
| CY1125152T1 (el) | Συνθεσεις και μεθοδοι για τη μειωση της νεοαγγειωσης του οφθαλμου | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1122707T1 (el) | Ετεροκυκλικοι αναστολεις γλουταμινασης | |
| CY1118969T1 (el) | Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak | |
| CY1118695T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
| CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
| CY1120334T1 (el) | Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων | |
| CY1121360T1 (el) | Αναστολεις dna-pk | |
| CY1122275T1 (el) | Μεσεγχυματικα στρωματικα κυτταρα και χρησεις που σχετιζονται με αυτα | |
| AR094997A1 (es) | Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos | |
| ECSP12012326A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| EA201790323A1 (ru) | Ингибиторы протеинкиназы c и способы их применения | |
| CY1119433T1 (el) | Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες | |
| CY1118135T1 (el) | Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| CY1117745T1 (el) | Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
| EA201891262A1 (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, их применение для лечения эозинофильных заболеваний | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| CY1117426T1 (el) | Παρεντερικη χορηγηση ταπενταδολης |